Braveheart Bio IPO
Braveheart Bio, Inc. · Clinical-stage biopharmaceutical (cardiovascular)
- Issue price
- $18per share
- Issue size
- $382.5M2,12,50,000 shares
- Face value
- To be announcedper equity share
- Lot size
- To be announcedMin. investment shown once set
- PricingWed, 2026
Information only, not investment advice. This page provides information compiled from official SEC filings for information purposes only. It is not investment advice or a recommendation to buy or sell any security. IPO investments involve risk, including loss of principal; read the prospectus carefully before investing.
Issue details
- Issue type
- Firm commitment, fresh issue
- Fresh issue
- 2,12,50,000 shares ($355.73M)
- Offer for sale
- None
- Total issue
- 2,12,50,000 shares ($382.5M)
- Face value
- —
- Listing at
- Nasdaq
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Special quotas
- directed_share_program
- 10,62,500 shares
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Valuation
Three months ended March 31, 2026- EPS (basic)
- -$2.08
- EPS (diluted)
- -$2.08
- EPS (basic) (Year ended December 31, 2025)
- -$17.2
- EPS (diluted) (Year ended December 31, 2025)
- -$17.2
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Financials
Consolidated, restated · ₹ crore| Period ended | 31 Mar 20263 months | 31 Dec 202512 months | 31 Mar 20253 months |
|---|---|---|---|
| Profit after tax | -1.43 | -6.61 | -0.01 |
| Net worth | -7.84 | — | — |
| Total assets | 8.19 | — | — |
Periods shorter than 12 months are shown as reported and are not annualised.
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
About the company
Braveheart Bio is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and related cardiovascular diseases. Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor licensed from Jiangsu Hengrui and is being prepared for global Phase 3 trials in obstructive and non-obstructive HCM.
- Incorporated
- 2024
- Industry
- Clinical-stage biopharmaceutical (cardiovascular)
- Sector
- Healthcare and Pharma
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Entities affiliated with Forbion | 27.80% | 21.00% |
| OrbiMed Private Investments IX, LP | 15.60% | 11.80% |
| AH Bio Fund IV, L.P. | 13.90% | 10.50% |
| Travis Murdoch, M.D. | 12.60% | 9.50% |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 11.30% | 8.50% |
| ES Braveheart Aggregator, L.P. | 5.20% | 3.90% |
| Frazier Life Sciences Public Fund, L.P. | 5.20% | 3.90% |
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Advance BHB-1893 development in obstructive HCM, including a Phase 3 trial | 9.00 |
| Advance BHB-1893 development in non-obstructive HCM, including a Phase 3 trial | 10.00 |
| Fund R&D personnel and overhead for both programs | 13.50 |
| Working capital and general corporate purposes | Set with price |
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesSource: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
Contacts
Source: Final prospectus (Form 424B4) dated 6 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price ($18) appear here after the shares list on Nasdaq.
Work out the gain or loss on allotted shares after charges →
Frequently asked questions
What is the Braveheart Bio IPO price band?
The final issue price is $18 per share.
Where will Braveheart Bio shares list?
On Nasdaq.
How will the money raised be used?
$90M for , $100M for , $135M for , and the rest for the other stated purposes.
Related IPOs
More healthcare and pharma IPOs
- Latigo Biotherapeutics$18Listed
- BlossomHill Therapeutics$16Listed
- Vogenx$13Listed
- Attovia Therapeutics$17Listed
Also managed by Goldman Sachs & Co. LLC
All Goldman Sachs & Co. LLC IPOs →Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.